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Abstract Background: Children are frequently prescribed medication ‘off-label’,
meaning there has not been sufficient testing of the medication to determine its
safety or effectiveness. The main reason this safety knowledge is lacking is due to
ethical restrictions that prevent children from being included in the majority of
clinical trials.
Methods: Multiple measures of association are calculated for each drug and med-
ical event pair and these are used as features that are fed into a classifier to
determine the likelihood of the drug and medical event pair corresponding to an
adverse drug reaction. The classifier is trained using known adverse drug reactions
or known non-adverse drug reaction relationships.
Results: The novel ensemble framework obtained a false positive rate of 0.149, a
sensitivity of 0.547 and a specificity of 0.851 when implemented on a reference set
of drug and medical event pairs. The novel framework consistently outperformed
each individual simple study design.
Conclusion: This research shows that it is possible to exploit the mechanism of
causality and presents a framework for signalling adverse drug reactions effectively.
Key Points
– The ensemble of simple study designs outperformed each single simple study
design when considering both the overall ability to rank adverse drug reactions
and the signalling performance at a natural threshold.
– The ensemble method is adaptable as it can incorporate any new measures of
association that are propose over time.
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– The results of the paper highlight the potential benefit of applying supervised
learning for adverse drug reaction signalling.
1 Introduction
There is an abundance of evidence to support the impression that side effects in
children currently present a significant public health problem [2,7]. When there is
a causal relationship between a drug and medical event it is termed an adverse
drug reaction (ADR). Children of all ages can suffer from diseases that require
them to take medication but the suitability of drugs in the paediatric population
(0-17 years old) is generally unexplored. The majority of paediatric prescriptions
are ‘off-label’ meaning the licensed medication is used in situations that have not
had sufficient investigation to determine the drug efficiency or safety. Examples of
off-label prescriptions are prescribing a different dosage or frequency than recom-
mended, prescribing a drug for a different indication than the drug was tested for
or prescribing the drug to age groups such as children where the drug has not been
extensively evaluated. The paediatric population are rarely involved in clinical tri-
als, so there is little evidence available to determine if a medication is efficient and
safe [18] and many drugs do not have licenses for children. A study that observed
a paediatric hospital in Derby, UK found that 23% of the prescribed drugs were
off-label and this was lower than the off-label rate observed in four other european
hospitals [7].
The problem with ‘off-label’ prescribing within the paediatric population is
that there are clear physiological differences between adults and children, so the
efficiency and safety knowledge discovered during clinical trials in the adult pop-
ulation cannot be accurately extrapolated for the paediatric population [5]. Con-
sequently, there has been a recent demand for incorporating more children into
randomised controlled trials [6] so drug efficiency and safety can be directly evalu-
ated for children. In addition to being able to assess the efficiency of drugs within
the paediatric population and determine suitable dosages, there are also advan-
tages for the children enrolled in trials such as access to new medicine that may
reduce morbidity. However, there are also many downsides including both physical
and mental discomfort, separation from parents [6] and the standard risks associ-
ated with adult clinical trials [13]. These downsides may be magnified in children
due to potential errors in initially estimating ‘adult equivalent’ doses, and due to
additional impacts of drugs on still-developing tissues. In the worse case, a clinical
trial could result in child mortalities. Therefore, if possible, it is more preferable
to develop alternative means to identify ADRs that do not have these negative
effects.
Pharmacovigilance is the study of prescription drug ADRs, including the col-
lection of suitable data and their detection and prevention. As the clinical trial
data for the paediatric population is lacking, a key resource for paediatric pharma-
covigilance is the spontaneous reporting system database [3,1]. The spontaneous
reporting systems amalgamate the suspected cases of ADRs that are voluntarily
reported within a population. For example, in the UK if a patient is prescribed a
drug and experiences an unexpected medical event then their doctor or the patient
can report the suspected ADR via the yellow card scheme by filling out a form. All
the yellow card scheme reports are then combined into a spontaneous reporting
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system database that is used to identify ADRs. As the database only contains
reports detailing cases when a drug is taken and a suspected ADR occurs, and not
the cases when a drug is taken and no ADRs is suspected, the frequency that drugs
are prescribed is unknown. Furthermore, as the reporting is done voluntarily, it is
common for data to be missing, incorrect or duplicated [4]. Consequently, there
are no current algorithms that can be applied to spontaneous reporting system
databases that are capable of detecting ADRs with a high accuracy, nor are the
algorithms able to quantify the frequency that the ADRs occur. It is the combi-
nation of a lack of clinical trials coupled with the general SRS limitations that
makes the paediatric population potentially more susceptible to ADRs. Research
into developing novel algorithms that are able to efficiently and effectively dis-
cover qualitative and quantitative ADR information for the paediatric population
is required to reduce child morbidities and mortalities.
A new type of database, called the longitudinal observational database, has
started to emerge as a potentially new source of ADR information. The longitudi-
nal observational database contains sequences of patients’ medical data often span-
ning decades of years and offers a new perspective for ADR discovery. One exam-
ple of a longitudinal observational database is The Health Improvement Network
(THIN) database that contains medical records extracted directly from general
practitioners’ databases across the UK (www.thin-uk.com). The THIN database
contains validated personal information about each patient in the database includ-
ing their year of birth and gender. There is also a complete medical record and
prescription history for each patient during the time they have been registered at
the practice. However, patients may not inform their doctors of all the medical
events they experience, especially minor ones, and use of over-the-counter medica-
tion for self-treatment is unlikely to be recorded. As the THIN database contains
information about how many patients are prescribed a drug, it may be possible to
extract quantitative information about ADRs. The effect of dosage and frequency
of prescription could also be investigated to identify the optimal treatment for
each child. This knowledge could then be used to help personalise medication for
paediatric patients based on their medical state, age and gender.
Several methods have been presented to identify ADR signals using longi-
tudinal observational databases, although comparisons have concluded that the
methods generally have a high false positive rate [19,16]. These algorithms in-
clude cohort techniques [10], case-series approaches [20], case-control approaches
[9], disproportionality analysis [21] or a mixture of the previously mentioned tech-
niques [14]. In addition to being limited by a high false positive rate, many of
these algorithms require the use of the patient’s medical history years prior to the
drug prescription of interest and this limits their ability for use on the paediatric
population as a long medical history is often not available (if a child is very young).
The case control method compares the prevalence of the drug within the popu-
lation of patients experiencing the medical event and the prevalence of the drug
within a population of patients that have similar covariates but do not experience
the medical event. However, the case control technique applied to the paediatric
population is likely to introduce confounding as children experiencing a medical
event may have a serious disorder that makes them susceptible to other illnesses,
whereas children not experiencing the medical event could be very healthy. Sim-
ilarly, comparing children who take a drug with children not taking a drug may
introduce confounding by indication [8] as children who do not take any medica-
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tion are likely to be very healthy due to a lack of chronic or degenerative illnesses
whereas children who require certain medication are likely to be very unhealthy.
It follows that a novel method that does not suffer from confounding by indica-
tion or require long periods of historic medical history should be more effective at
signalling ADRs.
Recently, a supervised framework [17] that learns from known ADRs has been
proposed to signal ADRs by using features based on the Bradford Hill causality
criteria, criteria that are frequently used to determine causality. This framework
was shown to perform well, and obtained a low false positive rate even when
the frequency of the ADR was low. Unfortunately, the calculation of many of
the Bradford Hill features require knowledge of a long medical history and this
is often not available for paediatric patients. Consequently, the framework using
Bradford Hill criteria based features faces difficulties when applied to detect ADRs
within the paediatric population. One possible solution would be to implement an
analogous framework that uses features based on the counterfactual method for
causal inference, as these features can be chosen such that a large medical history
is not required. This may enable rapid detection of paediatric ADRs and the
framework may yield a low false positive rate. The main benefit of this method is
that it does not have the risks associated with clinical trials.
In this paper we aim to investigate whether an ensemble of specifically chosen
simple study designs can signal acute ADRs within the paediatric population with
a low false positive rate. A comparison will be implemented to determine whether
the ensemble offers an improvement over each individual simple study design. The
ensemble requires generating multiple distinct measures of association between a
drug and medical event based on the counterfactual method for causal inference.
However, each measure of assocaition will be chosen such that a distinct type
of main confounding effect will be introduce. The motivation of combining these
measures of association via an ensemble is that it may be possible to exploit
any causal mechanism structures. Using drug and medical event pairs definitively
known to represent ADRs or non-ADRs, the various measures of association are
calculated for each drug and medical event pair to generate the labelled data used
to train a random forest classifier. The measures of association for any drug and
medical event pair with an unknown ADR status can then be calculated and fed
into the trained random forest to determine whether the pair corresponds to an
ADR.
The objective of this paper is to investigate whether an ensemble of simple
study designs can be implemented to signal acutely occurring side effects effectively
within the paediatric population by using historical longitudinal data. The major-
ity of pharmacovigilance techniques are unsupervised, but this research presents
a supervised framework.
2 Material
The THIN database contains temporal medical and therapy records for over 11
million UK patients. We used a subset of the THIN database for this research which
contained records for 4 million patients. Within the subset, there were a total of
30191726 medical events recorded for 1.7 million patients when they were 17 years
old or less. For each patient, their year of birth, gender and other personal details
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are known. Each medical record specifies the patient that the record corresponds
to, the record date and the medical event experienced by the patient. The medical
events have a tree structure, with the medical event becoming more specific as
its node depth (i.e., the length of the path from the root to the node) increases.
Therefore, medical event nodes with a depth of 1 are the most general and medical
event nodes with a depth of 5 are the most specific.
Each prescription within the THIN database contains details about the spe-
cific drug prescribed and contains a code corresponding to the drug known as the
British National Formulary (BNF) code [11]. The BNF code has a hierarchal struc-
ture that can be used to identify similar drugs. For example, BNF codes starting
with 05 (e.g., 05-xx-xx-xx) correspond to drugs used to treat infections, and BNF
codes starting with 05-01-01 (e.g., 05-01-01-xx) correspond to penicillins. A drug
family is the set of drugs with the same BNF code. For example, the drug family
benzlypenicillin sodium and phenoxymethlypenicillin have a corresponding BNF
code of 05-01-01-01 the drug family penicillinase-resistant penicillins have a BNF
code of 05-01-01-02 and the drug family broad-spectrum penicillins have a BNF
code of 05-01-01-03. These are the three drug families used to evaluate the novel
framework presented in this paper. The number of records for each of the drug
families in the THIN database is presented in Table 1. These drug families were
chosen as they are frequently prescribed so their ADRs are generally well known
and the creation of a reference set of definitive ADRs and non-ADRs was possible.
3 Methodology
3.1 Ensemble of Simple Studies Design Framework Overview
The proposed Ensemble of Simple Studies Design (ESSD) framework for signalling
the acute ADRs that occur within the paediatric population is:
1. Generate simple studies labelled data
– Choose n drug families of interest, where each drug family is denoted by
Dk, k ∈ [1, n].
– Determine the risk medical events (RMEDk), these are all the medical
events that are potential acutely occurring ADRs to the drugs in Dk.
– For each drug family Dk and medical event ∈ RMEDk pair, determine
whether the medical event is a known ADR or non-ADR of the drug family
Dk and add labels. The label for the i
th pair is denoted by yi. For example,
if the ith pair corresponds to an ADR then yi = 1 but if the i
th pair
corresponds to a non-ADR then yi = 0.
– Generate the features for each pair (Dk+event∈ RMEDk) by applying the
simple study designs to calculate multiple estimated causal effect values
(the measure of association). The feature vector for the ith pair is denoted
by xi.
2. Train a random forest model using the labelled data ({(xi, yi)})
– Apply 20-fold cross validation to tune the random forest classifier.
– Select the optimal model parameter by considering the classifiers general
ability to rank pairs corresponding to ADRs above pairs corresponding to
non-ADRs.
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3. Apply the trained random forest classifier to the simple study design features
of any unlabelled drug family and medical event pair (not known to correspond
to an ADR or non-ADR) and classify the pair as an ADR or non-ADR.
3.1.1 Risk Medical Events
For each drug family Dk, the medical events investigated are determined using
temporal information. As we are interested in acutely occurring ADRs, we restrict
our attention to only investigate medical events that are observed within the month
after a prescription of any drug within Dk is first prescribed. A month was chosen
to be a suitable trade off to enable a sufficient amount of time for the patient
to report the medical event while not introducing a surplus quantity of noise.
Therefore, given a drug family Dk, the risk medical events of Dk (RMEDk) are
defined as the set of all medical events that are observed for a minimum of three
patients within the month after any prescription of a drug within Dk. We chose
to add a limit of three or more patients experiencing the potential ADR as it is
difficult to determine whether a medical event is an ADR if it is experienced by
less than three patients.
3.1.2 Generating Features
For each drug family (Dk) and medical event ∈ RMEDk pair, we extract six
different estimates of the causal effect of Dk on the medical event. These are the
six simple study designs. The target population is the patients prescribed Dk and
the etiological time period (the period we investigate) is the month after the first
prescription. The estimates of the causal effect are calculated by either using a
different target population (Target Substitution) or using a different etiological
time period in (Etiological Substitution).
x1: Etiological Substitution (SSD1)- The causal effect is approximated by com-
paring the risk of the medical event during the month after the prescription
for the target population with the risk during the month before the prescrip-
tion for the target population. The main confounding effect is caused by a
covariate of ‘medical state’ as the target population medical states are likely to
change between the month before and the month after the prescription. This
causal effect estimate is likely to be large for progressive medical events (e.g.,
progressions of the cause of taking the drug) even though they are not caused
by the prescription.
x2: Etiological Substitution (SSD2)- The causal effect is approximated by com-
paring the risk of the medical event during the month after the prescription
for the target population with the risk during the year after for the target
population. The main confounding effect is a covariate of ‘medical sate’, but
unlike x1 the causal effect estimate is likely to be small for progressive medical
events that become more common as the population ages and large for medical
events that occurred acutely after the drug.
x3: Target Substitution (SSD3)- The causal effect is approximated by comparing
the risk of the medical event during the month after the prescription for the
target population with the risk during a randomly chosen month for a substi-
tute population that matches the target population on age and gender. The
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main confounding effect is caused by a covariate of ‘indication’ as the target
population all have certain illnesses causing them to require the drug but the
substitute population does not. This causal effect estimate is likely to be large
for medical events linked to the indication (i.e., the cause of taking the drug).
x4: Target Substitution (SSD4)- The causal effect is approximated by comparing
the risk of the medical event during the month after the prescription for the
target population with the risk during the month after for a substitute popula-
tion that are given a similar drug (i.e., a similar BNF code) and have the same
indications. The main confounding effects are caused by a covariate of ‘medical
caution’ as patients may be prescribed different drugs for the same indication
due to medical cautions (i.e., one patient has kidney issues preventing them
from having the standard medication) or covariates of ‘age and gender’ as age
and gender may influence the choice of drug prescribed.
x5: Etiological Substitution (SSD5)- First, a mapping is performed to ‘generalise’
the medical event descriptions. This is done by mapping medical event nodes
that have a depth greater than 3 to their depth 3 ‘parent node’. The causal
effect is then approximated using the mapped data by comparing the risk
of the corresponding depth 3 ‘parent node’ medical event during the month
after the prescription for the target population with the risk during the month
before for the target population. This causal effect measure is less vulnerable
to covariates of ‘medical event recording’, where different medical events that
correspond to the same/similar illness can be recorded due to redundancy or
illness progression.
x6: Etiological Substitution (SSD6)- First, a mapping is performed to ‘generalise’
the medical event descriptions. This is done by mapping medical event nodes
that have a depth greater than 4 to their depth 4 ‘parent node’. The causal
effect is then approximated by comparing the risk of the corresponding depth 4
‘parent node’ medical event during the month after the prescription for the tar-
get population with the risk during the month before for the target population.
This causal effect measure is less vulnerable to a covariate of ‘medical event
recording’, where different medical events that correspond to the same/similar
illness can be recorded due to redundancy or illness progression.
The vector xi = (x
1
i , x
2
i , ..., x
6
i ) contains the six estimates of the causal effect
for the i th drug family and medical event pair. We also create three additional
features from the original,
x7i =
{
x1i /x
2
i if |x
2
i | > 0
x1i else
x8i =
{
x1i /x
4
i if |x
4
i | > 0
x1i else
x9i =
{
x1i /x
5
i if |x
5
i | > 0
x1i else
These additional features indicate how much the simple study design association
measures deviate when considering time, similar patients or the specificity of the
medical event. So the complete feature vector for each drug family and medical
event pair is xi = (x
1
i , x
2
i , ..., x
9
i ) ∈ R
9.
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3.1.3 Random Forest Classifier
A random forest is a supervised classifier. The task of supervised learning is to
use the training data to learn a mapping between the feature vector and the
class. This mapping can then be used to predict the class for unseen data. The
random forest is known as a ensemble classifier as it trains and combines weak
and diverse classifiers. Each weak classifier is a decision tree that uses a subset of
the available features (the simple design study measures of association) to predict
the class (ADR or non-ADR). The advantages of the random forest classifier is
that it can have features that are both discrete and continuous and does not
require the features to be pre-processed (e.g., centred and scaled). The parameter
of the random forest that needs to be chosen is the number of features that each
decision tree can use, this is referred to as mtry. In this research we used the R
implementation of the random forest [12].
The random forest is trained using the labelled drug family and medical event
pair data, XL = {(xi, yi)| the label is known }. We applied 20-fold cross valida-
tion, this means that the data are partitioned into 20 sets and for each set the
random forest is trained on the other nineteen sets and then apply to predict the
class of each data-point within the set. The trained random forest is then evalu-
ated by a user defined criteria, in our case the area under of receiver operating
characteristic curve (AUC), and the average value corresponding to this measure
over the twenty sets determines how well the random forest has performed. This
performance measure is used to select the parameter mtry, as various random
forests are train with difference values of mtry and the mtry that results in the
highest AUC is selected. When we refer to the trained random forest we mean the
random forest that has been trained using the mtry value that was optimal.
3.2 Evaluation
To evaluate the ESSD framework, we created a reference set of drug families and
medical events pairs that are known to be ADRs or non-ADRs. The drug families
used to create the reference set are the penicillins with the BNF codes 05-01-01-
01, 05-01-01-02 and 05-01-01-03. The reference is used to train the random forest
and evaluate it. The reference set data corresponding to two of the drug family
is used as labelled data to train the random forest and the reference set data
corresponding to the remaining drug family is used for evaluation.
3.2.1 Creating the Reference Set
The reference set was created by investigating all the RMEDk for eachDk. Medical
events that are listed as side effects on the BNF website or the medical event states
the occurrence of a adverse event or the medical event is candidiasis as antibiotics
are known to cause this were labelled as ADRs. Any medical event with a cause
that is known and is not related to the penicillins (e.g., impetigo, worms, diabetes)
was labelled as non-ADRs and a selection of medical events that are likely to be
related to the cause of taking the drug were also labelled as non-ADRs. The labels
corresponding to medical events that are likely to be related are most likely to be
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incorrect out of all the labels as it is difficult to show that a medical event is not
an ADR, as even events that cause the drug to be taken could also be ADRs.
3.2.2 Evaluation Measures
The ESSD framework is evaluated by considering its ability to signal ADRs at its
natural threshold and its ability to rank drug family and medical event pairs by
how likely they correspond to ADRs. The ESSD is compared with each individual
simple study design (SSDi).
The natural threshold evaluation measures are the number of true positives
(TP), this is the number of pairs corresponding to ADRs that the method classes as
ADRs and the number of false positives (FP) is the number of pairs corresponding
to non-ADRs that the method classes as ADRs. Similarly, the number of false
negatives (FN) is the number of pairs that correspond to ADRs but the method
classes as non-ADRs and the number of true negatives (TN) is rhe number of pairs
that correspond to non-ADRs and the method classes as non-ADRs. The natural
threshold measures can be calculated as:
Sensitivity = TP/(TP + FN)
Specificity = TN/(FP + TN)
False positive rate (FPR) = FP/(FP + TN)
(1)
The general ranking ability of the methods are measured by the average pre-
cision (AP) and the AUC. The AUC is the area under the curve of the sensitivity
plotted against 1 minus the specificity for various thresholds. The AUC can be
interpreted as the probability of a uniformly chosen ADR pair being ranked above
a uniformly chosen non-ADR pair. If a method performs poorly at its natural
threshold but has a high AUC, then this may mean the natural threshold needs
to be modified.
4 Results
The ESSD framework was evaluated three times. Each time the reference set data
for two of the drug familities were used to train the random forest and the reference
set data for the third drug family was used for evaluation. A table containing the
full reference set data and the confidences returned by the ESSD framework can
be found in the electronic supplementary material. A summary of each of the three
evaluations is presented in Table 2. The optimal mtry obtained when training the
model is presented and also the result of the AUC for the cross-validation.
At their natural thresholds, the ESSD obtained a lower overall FPR of 0.149
compared to the other methods that obtained FPRs between 0.184 − 0.716. The
ESSD had a sensitivity of 0.547. Although other methods obtained a higher sensi-
tivity, they also had a very high false positive rate (≥ 0.532) which is not desirable.
The results of methods at their natural thresholds for each individual evaluation
are presented in Table 3 and the overall results with the sensitivity, specificity and
false positive rate are displayed in Table 4.
The general ranking ability of the ESSD was consistently higher than the other
methods with AUC values of 0.814, 0.806 and 0.813 for the evaluations 1 to 3
10 Jenna M. Reps et al.
respectively. The highest AUC value out of all the other methods was 0.813, 0.794
and 0.729 for the evaluations 1 to 3 respectively. The AP value obtained by the
ESSD was also greater for each evaluation, with the ESSD obtaining 0.615, 0.659
and 0.717 for evaluation 1 to 3 respectively, whereas the highest AP obtained by
any other method over evaluation 1 to 3 was 0.587, 0.508 and 0.493 respectively.
The results of the general ranking ability at presented in Table 5.
5 Discussion
The results show that the ESSD framework consistently outperformed the indi-
vidual simple study design measures. It consistently obtained a higher AP and
AUC for all three BNF families investigated. At its natural threshold the ESSD
framework was able to signal just over half the true ADRs while only signalling
approximately 15% of the non-ADRs. However, as it is difficult to prove a medical
event is not an ADR, some of the non-ADR labels may be incorrect, so the proba-
bility of signalling an non-ADRs may actually be lower (i.e., the FPR is probably
less than the value obtain within this research). The ESSD framework is also ef-
ficient, as the simple measures can be calculated readily and the classifier can be
trained quickly. Once trained, the prediction is fast and could be implemented
regularly when new data is added to the longitudinal database. As the ESSD has
a low false positive rate and is efficient, it may be a useful framework to implement
for signal generation. However, the signals that are generated will still need to be
refined as it does not have a zero false positive rate.
There have been few attempts to apply supervised learning to the field of
pharmacovigilance but this is an interesting area, as the results of supervised clas-
sifier can be improved when more labelled data is available. Therefore, supervised
methods should improve over time as as more ADR knowledge is gained. It may be
possible to feedback the results of the supervised methodologies to further improve
them via methods such as semi-supervised techniques. The ESSD also has the ad-
vantage of being adaptable, as it could incorporate new measures of association
that get proposed over time as features.
In this paper we have trained the ESSD using similar BNFs to the BNF used
for the evaluation. The justification for this is that similar BNF drugs are likely to
have similar underlying patterns. It would be interesting to see whether the random
forest within the ESSD framework could be trained on a variety of different BNFs
and still perform well. This would indicate whether the underlying structures are
independent of the drug.
One difficulty that was noticed with the ESSD framework is the choice of
BNF to use to calculate the similar BNF measure of association (SSD4). For the
penicillins that was easy as the BNF codes are numerous, but for BNF families
such as the proton pump inhibitors, a closely resembling BNF family is difficult to
determine and the wrong choice could lead to different models with various perfor-
mances. To overcome this the methodology may need to be applied to individual
drugs rather than BNF facilities, but this could be problematic when the drug
is rarely prescribed and therefore rarely recorded within the database. However,
with the combination of longitudinal healthcare databases now becoming common
[15], even rarely prescribed drugs should have a sufficient number of occurrences
in the combined database.
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6 Conclusion
In this paper we have proposed a novel framework, called the ensemble of simple
study designs (ESSD), specifically for signalling acute ADRs within the paediatric
population. The framework does not require knowledge of a patient’s medical his-
tory of more than a month prior to the prescription. The results show that the
ESSD can outperform each individual simple study design measures and appears
to be more consistent. The ensemble still misclassifies some non-ADRs but it ob-
tained a false positive rate of 0.149, making it competitive with existing methods.
The advantage of this methodology is that it is supervised, so as new ADRs are
discovered its performance should increase as more labelled data will be available
for training it.
Future work could involve researching new methods for refining the ADR sig-
nals that are generated and reducing the false positive rate further or investigating
different features based on alternative substitutions for the hypothetical counter-
factual situation. For example, features that deal with alternative forms of con-
founding such as the time of the year could be incorporated. It is also of interest to
see whether adding more complex study design methods such as Temporal Pattern
Discovery [14] or HUNT [10] can improve the ensemble and a comparison between
these methods and the ESSD would be useful.
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Table 1 Details about the records within the subset of The Health Improvement Network
(THIN) database for a selection of three penicillin drugs prescribed to patients aged 17 years
or less.
Drug Family BNFa Number of Prescriptions
Total First in 3 months
benzlypenicillin sodium and phe-
noxymethlypenicillin
05-01-01-01 1520866 456926
penicillinase-resistant penicillins 05-01-01-02 310622 252947
broad-spectrum penicillins 05-01-01-03 6490455 1448563
aBritish national formulary code.
Table 2 The details of the evaluation experiments.
Evaluation Training/testing Set Optimal mtry Training AUCa Evaluation Set
1 05− 01− 01− {02, 03} 4 0.885 05− 01− 01− 01
2 05− 01− 01− {01, 03} 6 0.827 05− 01− 01− 02
3 05− 01− 01− {01, 02} 9 0.875 05− 01− 01− 03
aArea under the ROC curve obtained by the 20-fold cross validation.
Table 3 For each evaluation experiment ,the number of TP, FP, FN and TN returned for the
ensemble of simple study designs (ESSD) and each individual simple study design (SSDi).
1 2 3
Method TPa FPb FNc TNd TP FP FN TN TP FP FN TN
ESSD 9 9 8 30 9 6 9 40 17 6 12 50
SSD1 17 21 0 18 15 31 3 15 26 33 3 23
SSD2 17 22 0 17 18 42 0 4 29 37 0 19
SSD3 5 4 12 35 5 13 13 33 17 17 12 39
SSD4 2 4 15 35 2 17 16 29 4 5 25 51
SSD5 17 19 0 20 17 26 1 20 25 30 4 26
SSD6 17 19 0 20 15 29 3 17 24 31 5 25
aTrue positive bFalse positive cFalse negative dTrue negative
Table 4 The average number of TP, FP, FN and TN returned for the ensemble of simple study
designs (ESSD) and each individual simple study design (SSDi) and the overall specificity,
sensitivity and false positive rate (FPR).
Method TPa FPb FNc TNd Sensitivity Specificity FPR
ESSD 35 21 29 120 0.547 0.851 0.149
SSD1 58 85 6 56 0.906 0.397 0.603
SSD2 64 101 0 40 1 0.284 0.716
SSD3 27 34 37 107 0.422 0.759 0.241
SSD4 8 26 56 115 0.125 0.816 0.184
SSD5 59 75 5 66 0.922 0.468 0.532
SSD6 56 79 8 62 0.875 0.440 0.560
aTrue positive bFalse positive cFalse negative dTrue negative
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Table 5 A comparison of the general ADR ranking ability of the ensemble of simple study
designs (ESSD) and each individual simple study design (SSDi).
1 2 3 Average
Method AUCa APb AUC AP AUC AP AUC AP
ESSD 0.814 0.615 0.806 0.659 0.813 0.712 0.811 0.662
SSD1 0.797 0.559 0.606 0.362 0.678 0.457 0.694 0.459
SSD2 0.785 0.548 0.741 0.430 0.729 0.493 0.752 0.490
SSD3 0.602 0.499 0.484 0.292 0.629 0.433 0.572 0.408
SSD4 0.477 0.316 0.322 0.217 0.459 0.333 0.419 0.289
SSD5 0.797 0.558 0.794 0.508 0.698 0.448 0.763 0.505
SSD6 0.813 0.587 0.621 0.356 0.655 0.435 0.696 0.459
aArea under the ROC curve bAverage precision
